Skip to main content
Clinical Trials/NCT03320434
NCT03320434
Completed
Phase 2

A Single-Center, Randomized, Double-Masked, Vehicle and Active-Controlled, Dose-Ranging Phase 2 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model (Ora-CAC®)

ORA, Inc.1 site in 1 country120 target enrollmentOctober 13, 2017

Overview

Phase
Phase 2
Intervention
PRT-2761 0.5%
Conditions
Allergic Conjunctivitis
Sponsor
ORA, Inc.
Enrollment
120
Locations
1
Primary Endpoint
Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.

Registry
clinicaltrials.gov
Start Date
October 13, 2017
End Date
February 18, 2018
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
ORA, Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • be at least 18 years old
  • be willing and able to avoid all disallowed medications and contact lenses
  • must have a pregnancy test if of childbearing potential
  • must be able to read an eye chart from 10 feet away

Exclusion Criteria

  • must not have any allergies to the study medications
  • must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
  • must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial

Arms & Interventions

PRT-2761 0.5%

Intervention: PRT-2761 0.5%

PRT-2761 1%

Intervention: PRT-2761 1%

Patanol

Intervention: Patanol

Pred-forte

Intervention: Pred-forte

PRT-2761 0%

Intervention: PRT-2761 0%

Outcomes

Primary Outcomes

Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1

Time Frame: post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 1.

Conjunctival Redness was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no redness) to 4=severe (worst/most redness)). The conjunctival redness was averaged across all subjects at each time point.

Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15

Time Frame: post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 15.

Conjunctival Redness was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no redness) to 4=severe (worst/most redness)). The conjunctival redness was averaged across all subjects at each time point.

Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 15

Time Frame: post CAC exposure at 5, 7, and 10 minutes post CAC on Day 15

Ocular Itching was assessed by the subjects using a 0 to 4 point scale(0=none (best/no itching) to 4=severe (worst/most itching)). The ocular itching was averaged across all subjects at each time point.

Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1

Time Frame: post CAC exposure at 5, 7, and 10 minutes post CAC on Day 1

Ocular Itching was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no itching) to 4=severe (worst/most itching). The ocular itching was averaged across all subjects at each time point.

Study Sites (1)

Loading locations...

Similar Trials